Newron completes Ph II enrollment of ralfinamide
Newron completes Ph II enrollment in ralfinamide trial
Milan, Italy-based Newron Pharmaceuticals SpA, which is focused on novel central nervous system and pain therapies, has announced the completion of enrolment in a Phase II study with ralfinamide in post-surgical (dental) pain.
The Phase II, pilot, randomized, placebo-controlled, double-blind, parallel-group, multicenter trial was designed to determine the safety, tolerability and preliminary evidence of preventive analgesic efficacy of orally administered ralfinamide at a dose range of 320mg/480mg per day, compared to placebo, in patients with third molar, post-extraction, dental pain. It was performed in 15 study centers in India and Romania.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze